Blockade of TIGIT-PVR Axis can Treat Breast Cancer
DOI :
https://doi.org/10.17161/mjusc.v1i1.18570Mots-clés :
TIGIT, Checkpoint Inhibitor, Cancer, Breast, PVR, immunologyRésumé
This review covers the identification and application of anti-TIGIT antibodies as checkpoint inhibitors for the treatment of triple-negative breast cancers. The original article, Targeting the TIGIT-PVR Immune Checkpoint Axis as Novel Therapeutic Option in Breast Cancer, was published by Stamm et al. in Oncoimmunology in October of 2019.
Téléchargements
Publiée
2022-10-03
Numéro
Rubrique
Reviews
Licence
![Creative Commons License](http://i.creativecommons.org/l/by-nc/4.0/88x31.png)
Ce travail est disponible sous licence Creative Commons Attribution - Pas d’Utilisation Commerciale 4.0 International.
© The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license.
Comment citer
Hernandez Garcia, A. (2022). Blockade of TIGIT-PVR Axis can Treat Breast Cancer. Midwestern Journal of Undergraduate Sciences, 1(1), 5. https://doi.org/10.17161/mjusc.v1i1.18570